AR034265A1 - Aminoacidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y el uso de aminoacidos para la preparacion de medicamentos para el tratamiento de dolores - Google Patents
Aminoacidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y el uso de aminoacidos para la preparacion de medicamentos para el tratamiento de doloresInfo
- Publication number
- AR034265A1 AR034265A1 ARP010104585A ARP010104585A AR034265A1 AR 034265 A1 AR034265 A1 AR 034265A1 AR P010104585 A ARP010104585 A AR P010104585A AR P010104585 A ARP010104585 A AR P010104585A AR 034265 A1 AR034265 A1 AR 034265A1
- Authority
- AR
- Argentina
- Prior art keywords
- unsubstituted
- preparation
- polysubstituted
- mono
- amino acids
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 6
- 208000002193 Pain Diseases 0.000 title abstract 4
- 150000001413 amino acids Chemical class 0.000 title abstract 4
- 230000036407 pain Effects 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 4
- 208000004454 Hyperalgesia Diseases 0.000 abstract 4
- 239000002253 acid Substances 0.000 abstract 4
- 150000007513 acids Chemical class 0.000 abstract 4
- 229920006395 saturated elastomer Polymers 0.000 abstract 4
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 abstract 2
- 150000008043 acidic salts Chemical class 0.000 abstract 2
- 230000002378 acidificating effect Effects 0.000 abstract 2
- 150000001447 alkali salts Chemical class 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
- 150000001450 anions Chemical class 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 2
- 150000001768 cations Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010015037 epilepsy Diseases 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 2
- 208000004296 neuralgia Diseases 0.000 abstract 2
- 230000002981 neuropathic effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000035154 Hyperesthesia Diseases 0.000 abstract 1
- 206010065390 Inflammatory pain Diseases 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010033664 Panic attack Diseases 0.000 abstract 1
- 208000004550 Postoperative Pain Diseases 0.000 abstract 1
- 208000005793 Restless legs syndrome Diseases 0.000 abstract 1
- 206010041415 Spastic paralysis Diseases 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 206010053552 allodynia Diseases 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000001773 anti-convulsant effect Effects 0.000 abstract 1
- 239000001961 anticonvulsive agent Substances 0.000 abstract 1
- 229960003965 antiepileptics Drugs 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- 230000000949 anxiolytic effect Effects 0.000 abstract 1
- 208000028683 bipolar I disease Diseases 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 231100001014 gastrointestinal tract lesion Toxicity 0.000 abstract 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 206010029864 nystagmus Diseases 0.000 abstract 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
La presente se refiere a aminoácidos, de la fórmula general (1), en la cual: uno de los radicales R1 y R2 representa alquilo C1-3, particularmente metilo, etilo, n-propilo o i-propilo, no sustituido o mono o polisustituido y el otro de los radicales R1 y R2 representa alquilo C3-10, particularmente n-propilo, i-propilo, n-butilo, i-butilo, butilo secundario, butilo terciario, pentilo, hexilo, heptilo u octilo, ramificados o no ramificados, saturados o no saturados, no sustituidos o mono o polisustituidos, o arilo o heteroarilo, particularmente fenilo, naftilo, furanilo, tiofenilo, pirimidinilo o piridinilo, no sustituidos o monosustituidos (preferiblemente con OCH3, CH3, OH, SH, CF3, F, Cl, Br o I), o cicloalquilo C3-8, particularmente ciclopropilo, ciclobutilo, ciclopentilo, ciclohexilo o cicloheptilo, no sustituidos o monosustituidos, en forma de sus racematos, enantiómeros, diastereómeros, particularmente mezclas de sus enantiómeros o diastereómeros o un de enantiómero o diastereómero individual; en forma de sus sales ácidas y básicas o sales con cationes o bases o con aniones o ácidos en forma de ácidos o bases libres, fisiológicamente tolerables, procedimiento para su preparación, medicamentos que contienen estos compuestos y el uso de aminoácidos de la fórmula general (1), en la cual: R1 y R2 representan independientemente entre sí alquilo C1-10 de cadena recta o ramificada, saturado o insaturado, no sustituido o mono o polisustituido, arilo, cicloalquilo C3-10 o heteroarilo, no sustituidos o mono o polisustituidos, o R1 y R2 representan conjuntamente un ciclo (CH2)3-6, saturado o insaturado, no sustituido o sustituido, en el cual 0 a 2 átomos de C pueden estar sustituidos por S, O ó NR4, estando elegido R4 entre H, alquilo C1-10, saturado o insaturado, ramificado o no ramificado, no sustituido o mono o polisustituido, en forma de sus racematos, enantiómeros, diastereómeros, particularmente mezclas de sus enantiómeros o diastereómeros o un enantiómero o diastereómero individual; en forma de sus sales ácidas o básicas o sales con cationes o bases o con aniones o ácidos fisiológicamente tolerables, o en forma de sus ácidos o bases libres; para la preparación de un medicamento para el tratamiento de dolores, particularmente dolores neuropáticos, crónicos y agudos, de epilepsia y/o de migranas, o para la preparación de un medicamento para el tratamiento de hiperalgesia y alodinia, particularmente hiperlagesia térmica, hiperalgesia mecánica, alodinia y crioalodinia o de dolores inflamatorios o postoperatorios, o para la preparación de un medicamento para el tratamiento de calores y otros desórdenes postmenopáusicos, esclerosis lateral amiotrofica (ALS), distrofia simpática refleja (RSD), parálisis espastica, síndrome de las piernas inquietas, nistagmo adquirido, afecciones psiquiatricas o neuropatológicas, tales como perturbaciones bipolares, ansiedad, ataques de pánico, modificaciones de carácter, comportamiento maníaco, depresiones, comportamiento maniaco-depresivo, neuropatía diabética dolorosa, síntomas y dolores resultantes de esclerosis múltiple o enfermedad de Parkinson, enfermedades neurodegenerativas tales como enfermedad de Huntington, enfermedad de Parkinson, epilepsia, lesiones gastrointestinales; dolores eritromelálgicos o postpoliomielíticos, neuralgia del trigémino o postherpética, o como anticonvulsivo, analgésico o ansiolítico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10048715A DE10048715A1 (de) | 2000-09-30 | 2000-09-30 | Verwendung von Aminosäure zur Behandlung von Schmerz |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR034265A1 true AR034265A1 (es) | 2004-02-18 |
Family
ID=7658376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010104585A AR034265A1 (es) | 2000-09-30 | 2001-09-28 | Aminoacidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y el uso de aminoacidos para la preparacion de medicamentos para el tratamiento de dolores |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20030229145A1 (es) |
| EP (1) | EP1326826A1 (es) |
| JP (1) | JP2004511459A (es) |
| AR (1) | AR034265A1 (es) |
| AU (1) | AU2001289936A1 (es) |
| CA (1) | CA2424089A1 (es) |
| DE (1) | DE10048715A1 (es) |
| HU (1) | HUP0302970A2 (es) |
| MX (1) | MXPA03002740A (es) |
| NZ (1) | NZ525417A (es) |
| PE (1) | PE20030617A1 (es) |
| PL (1) | PL361629A1 (es) |
| WO (1) | WO2002030871A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NI200300043A (es) | 2002-03-28 | 2003-11-05 | Warner Lambert Co | AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA. |
| US7659305B2 (en) | 2002-10-31 | 2010-02-09 | Pfizer Inc. | Therapeutic proline derivatives |
| CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| EP2196201A3 (en) | 2002-12-13 | 2010-12-08 | Warner-Lambert Company LLC | Combination of an alpha-2-delta ligand with a pdev inhibitor or a muscarinic antagonist to treat lower urinary tract symptoms |
| ATE449633T1 (de) | 2003-09-12 | 2009-12-15 | Pfizer | Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern |
| CA2540247C (en) | 2003-09-25 | 2011-01-25 | Warner-Lambert Company Llc | Prodrugs of amino acids with affinity for the .alpha.2.delta.-protein |
| US7354955B2 (en) | 2004-01-07 | 2008-04-08 | Abbott Laboratories | (2S)-amino(phenyl)acetic acid and derivatives as α2δ voltage-gated calcium channel ligands |
| DE102004022572B4 (de) | 2004-05-07 | 2012-02-16 | Infineon Technologies Ag | Integratorschaltung |
| EA200701852A1 (ru) | 2005-04-28 | 2008-04-28 | Пфайзер Лимитед | Производные аминокислот |
| WO2008031221A1 (en) * | 2006-09-12 | 2008-03-20 | Cephalin Pharmaceuticals Inc. | Isovaline for treatment of pain |
| US20080153888A1 (en) | 2006-12-22 | 2008-06-26 | Recordati Ireland Limited | Alpha-2-delta ligand/nsaid therapeutic treatment of lower urinary tract disorders |
| CN116655501A (zh) * | 2023-05-23 | 2023-08-29 | 岳阳市康利医药化工有限公司 | 一种异氰基乙酸乙酯工艺流程中的优化合成方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2854627C2 (de) * | 1978-12-18 | 1980-07-03 | Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt | Verfahren zur Herstellung von Aminocarbonsäurehydrochloriden bzw. Diaminocarbonsäure-di-hydrochloriden |
| CA1255037A (en) * | 1984-06-29 | 1989-05-30 | Barry L. Dickinson | Protective helmet made from a polyarylate |
| DE3664632D1 (en) * | 1985-04-05 | 1989-08-31 | Texaco Development Corp | Process for the synthesis of n-acetyl amino acids from olefins, acetamide and syngas |
| EP0342558B1 (en) * | 1988-05-16 | 1994-02-02 | G.D. Searle & Co. | 2-amino-4,5-methyleneadipic acid compounds for treatment of CNS disorders |
| NL9101380A (nl) * | 1991-08-13 | 1993-03-01 | Dsm Nv | Werkwijze voor de bereiding van een alfa-aminozuur, de overeenkomstige ester en amide. |
| DE4425068A1 (de) * | 1994-07-15 | 1996-01-18 | Degussa | Verfahren zur Herstellung optisch aktiver L-Aminosäuren, neue optisch aktive L-Aminosäuren mit raumerfüllenden Seitengruppen und deren Verwendung |
| IL125544A (en) * | 1996-03-14 | 2002-03-10 | Warner Lambert Co | Transformed cyclic amino acids and pharmaceutical preparations containing them |
| GB9621789D0 (en) * | 1996-10-18 | 1996-12-11 | Lilly Industries Ltd | Pharmaceutical compounds |
| JP3847934B2 (ja) * | 1997-02-14 | 2006-11-22 | 株式会社カネカ | γ−オキソ−ホモフェニルアラニン誘導体及びそれを還元してなるホモフェニルアラニン誘導体の製造方法 |
| CN1251579A (zh) * | 1997-04-07 | 2000-04-26 | Axys药物公司 | 治疗与丝氨酸蛋白酶－特别是类胰蛋白酶－活性有关的疾病的化合物与组合物 |
| AU1608399A (en) * | 1997-11-26 | 1999-06-15 | Axys Pharmaceuticals, Inc. | Substituted amidinoaryl derivatives and their use as anticoagulants |
| JP4205191B2 (ja) * | 1997-12-26 | 2009-01-07 | ダイセル化学工業株式会社 | α−アミノニトリル誘導体及びα−アミノ酸の製造方法 |
-
2000
- 2000-09-30 DE DE10048715A patent/DE10048715A1/de not_active Withdrawn
-
2001
- 2001-09-28 EP EP01969790A patent/EP1326826A1/de not_active Withdrawn
- 2001-09-28 CA CA002424089A patent/CA2424089A1/en not_active Abandoned
- 2001-09-28 NZ NZ525417A patent/NZ525417A/xx not_active IP Right Cessation
- 2001-09-28 WO PCT/EP2001/011230 patent/WO2002030871A1/de not_active Ceased
- 2001-09-28 HU HU0302970A patent/HUP0302970A2/hu unknown
- 2001-09-28 AR ARP010104585A patent/AR034265A1/es not_active Application Discontinuation
- 2001-09-28 PE PE2001000970A patent/PE20030617A1/es not_active Application Discontinuation
- 2001-09-28 AU AU2001289936A patent/AU2001289936A1/en not_active Abandoned
- 2001-09-28 PL PL36162901A patent/PL361629A1/xx not_active Application Discontinuation
- 2001-09-28 JP JP2002534260A patent/JP2004511459A/ja not_active Withdrawn
- 2001-09-28 MX MXPA03002740A patent/MXPA03002740A/es unknown
-
2003
- 2003-03-31 US US10/402,129 patent/US20030229145A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1326826A1 (de) | 2003-07-16 |
| NZ525417A (en) | 2005-11-25 |
| US20030229145A1 (en) | 2003-12-11 |
| MXPA03002740A (es) | 2003-07-28 |
| HUP0302970A2 (hu) | 2003-12-29 |
| WO2002030871A1 (de) | 2002-04-18 |
| PL361629A1 (en) | 2004-10-04 |
| DE10048715A1 (de) | 2004-05-19 |
| PE20030617A1 (es) | 2003-08-02 |
| AU2001289936A1 (en) | 2002-04-22 |
| JP2004511459A (ja) | 2004-04-15 |
| CA2424089A1 (en) | 2003-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR034265A1 (es) | Aminoacidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y el uso de aminoacidos para la preparacion de medicamentos para el tratamiento de dolores | |
| ES2552051T3 (es) | Derivados de acrilamido útiles como inhibidores de la transición de la permeabilidad mitocondrial | |
| ME02490B (me) | Hemijska jedinjenja | |
| JP2015503595A5 (es) | ||
| HRP20201473T1 (hr) | Inhibitori lizin gingipaina | |
| AR062387A2 (es) | El uso de un compuesto derivado de imidazo[1,2-a] piridina, y un medicamento que lo contiene | |
| CN100567279C (zh) | 烷基哌嗪-和烷基高哌嗪-羧酸酯衍生物、其制备方法及其作为faah酶抑制剂的用途 | |
| AR071267A1 (es) | Procedimiento para la produccion de 2-(4-(2-fluorobenciloxi )bencilamino ( ralfinamida ) o 2-(4-(3-fluorobenciloxi )bencilamino ( safinamida ) con alto grado de pureza, uso de dichos compuestos para la preparacion de un medicamento y composiciones farmaceuticas de los mismos | |
| PE20081485A1 (es) | Derivados de sulfonamida | |
| CU20130116A7 (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
| RU2014122335A (ru) | ХИНОЛИНКАРБОКСАМИДНЫЕ И ХИНОЛИНКАРБОНИТРИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ mGluR2-НЕГАТИВНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ | |
| JP2010514758A5 (es) | ||
| AR034158A1 (es) | Derivados de 1-aminobutano-3-ol sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y el uso de derivados de 1-aminobutano-3-ol sustituidos para la preparacion de medicamentos | |
| IN2014DN10538A (es) | ||
| AR034160A1 (es) | Sulfonilguanidinas, medicamentos que contienen estos compuestos y el uso de sulfonilguanidinas | |
| CL2011001088A1 (es) | Sal clorhidrato cristalina de 4-[2-(2,4,6-trifluorofenoximetil)fenil]piperidina; composicion farmaceutica que la comprende; y uso para tratar un trastorno doloroso, depresivo, afectivo, cognitivo, obesidad, sindrome de fatiga cronica, incontinencia urinaria por stress. | |
| JP2018534300A5 (es) | ||
| ES2343624T3 (es) | Derivados de prolina que tienen afinidad por la subunidad alfa-2-delta del canal de calcio. | |
| JP2024525561A (ja) | 化合物、組成物及び方法 | |
| PA8529801A1 (es) | Un nuevo compuesto derivado de la triptamina y sus analogos | |
| CO2017011010A2 (es) | Derivados de etinilo | |
| AR034159A1 (es) | Derivados de 5-amino-1-penten-3-ol sustituidos, procedimiento para su preparacion, medicamentos que contienen estos derivados y su uso para la preparacion de medicamentos | |
| AR057461A1 (es) | Derivados de pirazol, proceso de preparacion, composiciones farmaceuticas y usos | |
| AR061890A1 (es) | Sal xinafoato del etil ester de la 1-[[5-(1s)-aminoetil)-2-[8-metoxi-2(trifluorometil)-5-quinolil]-4-oxazolil]carbonil]-(4r)-[(ciclopropil-carbonil)amino]-l-prolina. | |
| IL198047A (en) | A selective tr-beta 1 agonist, a pharmaceutical product containing it and its use in the preparation of drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |